Inventiva Appoints New Leadership Team to Advance MASH Drug Lanifibranor Through Phase 3 Trial
Key Insights
Inventiva has appointed Dr. Jason Campagna as President of R&D and Chief Medical Officer to lead the development of lanifibranor, a first-in-class pan-PPAR agonist (search) for MASH (search) treatment.
Dr. Campagna brings extensive experience from Intercept, where he led the first-ever NDA submission for MASH (search) indication and designed advanced clinical programs.
Dr. Martine Zimmermann joins as Executive Vice President of Regulatory Affairs and Quality Assurance, bringing expertise in global regulatory strategy for chronic liver diseases.
Inventiva has strengthened its leadership team with two key appointments as the clinical-stage biopharmaceutical company advances its lead MASH (search) candidate lanifibranor through a pivotal Phase 3 trial. The company announced that Dr. Jason Campagna has been named President of R&D and Chief Medical Officer, while Dr. Martine Zimmermann joins as Executive Vice President of Regulatory Affairs and Quality Assurance.
Strategic Leadership Additions for MASH Program
Dr. Campagna brings significant experience in MASH (search) drug development from his previous role at Intercept, where he led the design and execution of advanced clinical programs, including the first-ever New Drug Application (NDA) submission in the MASH indication. His appointment comes at a critical juncture as Inventiva prepares for anticipated regulatory submissions for lanifibranor.
"Having led the design and execution of one of the field's most advanced clinical programs at Intercept—including the first-ever NDA submission in this indication—I've seen firsthand both the scientific complexity and the urgency of bringing effective therapies to patients with MASH (search)," Dr. Campagna commented. "I believe the promising results of the Phase 2b NATIVE trial reflect the thoughtful design of lanifibranor development program—and that's deeply exciting to me."
Dr. Zimmermann brings expertise in global regulatory strategy for chronic liver diseases, having been closely involved in leading regulatory approval of compounds for liver disease treatment, including a PPAR (search) compound, across multiple geographies including the US, Europe, and Japan.
Lanifibranor Development Program
Lanifibranor is a novel pan-PPAR agonist (search) currently being evaluated in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH (search) (metabolic dysfunction-associated steatohepatitis (search)), a common and progressive chronic liver disease (search). The company expects topline Phase 3 results from the NATiV3 trial in the second half of 2026.
The drug candidate has shown promising results in the Phase 2b NATIVE trial, which Dr. Campagna highlighted as reflecting the thoughtful design of the lanifibranor development program. With lanifibranor advancing through the Phase 3 NATiV3 registrational trial, the new leadership appointments position Inventiva to navigate the complex regulatory pathway for MASH (search) therapeutics.
Company Focus and Market Position
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with MASH (search) and other diseases with significant unmet medical need. The company is publicly listed on compartment B of the regulated market of Euronext Paris (ticker: IVA) and on the Nasdaq Global Market in the United States (ticker: IVA).
Dr. Zimmermann expressed enthusiasm about joining during this critical regulatory phase: "I'm excited to take on this leadership role at a time when Inventiva is entering a critical regulatory phase for lanifibranor, a first-in-class pan-PPAR agonist (search) for the treatment of MASH (search). I am now eager to apply that experience to support lanifibranor toward a potential approval."